Abatacept in Immune Checkpoint Inhibitor Myocarditis (NCT05335928)
AbatacepT foR ImmUne Checkpoint Inhibitor Associated Myocarditis (ATRIUM): A Phase 3, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept in ICI Myocarditis
🩺 Plain-English Summary (8th-Grade Level)
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.
Who can join: Review the eligibility criteria below.
Location: Cedars-Sinai Medical Center — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (31 Sites)
Showing the first 25 of 31 sites.
- Cedars-Sinai Medical Center — Los Angeles, California
- University of California Los Angeles — Los Angeles, California
- MedStar Health Research Institute, Georgetown University — Washington D.C., District of Columbia
- Moffitt Cancer Center — Tampa, Florida
- University of Chicago — Chicago, Illinois
- Franciscan Health — Indianapolis, Indiana
- University of Kansas Medical Center — Kansas City, Kansas
- University of Kentucky — Lexington, Kentucky
- Maine Health — Portland, Maine
- Johns Hopkins — Baltimore, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Boston Medical Center — Boston, Massachusetts
- Brigham and Women's Hospital — Boston, Massachusetts
- University of Michigan — Ann Arbor, Michigan
- Mayo Clinic — Rochester, Minnesota
- Robert Wood Johnson University Hospital — New Brunswick, New Jersey
- Columbia University Irving Medical Center — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- University of North Carolina Chapel Hill — Chapel Hill, North Carolina
- Cleveland Clinic — Cleveland, Ohio
- Lehigh Valley Health Network — Bethlehem, Pennsylvania
- University of Pennsylvania — Philadelphia, Pennsylvania
- Allegheny-Singer Research Institution — Pittsburgh, Pennsylvania
- University of Texas Southwestern — Dallas, Texas
📞 Contact the Study Coordinator
Phone: (617) 726-1019
Email: hkgilman@mgh.harvard.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Myocarditis Acute
- MCE Molecular Imaging for Myocarditis — Charlottesville, Virginia
- MYTHS - MYocarditis THerapy With Steroids — San Diego, California
Explore by condition: All Myocarditis Acute clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.